<p><b>TABLE OF INTERACTIONS WITH</b></p>

<p><b>POSACONAZOLE</b></p>

<p><b>See also: strong inhibitors of CYP3A4</b></p>

<p><b>From the French ANSM drug interactions document of </b></p>

<p><b>September 2016, pp. 179-180</b></p>

<table cellspacing="0" cellpadding="0" border="1">
<tbody>
<tr>
<td valign="top"><p><b>POSACONAZOLE</b></p>

<p><b>RxNorm: 282446 </b></p>

<p><b>ATC: J02AC04</b></p></td>
<td valign="top"><p><b>ANTICONVULSANT ENZYMATIC INDUCERS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>N03A-001</b></p></td>
<td valign="top"><p>Decrease of the plasma concentrations and of the effectiveness of the posaconazole</p>

</td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Clinical monitoring. If possible, plasma dosages of the posaconazole and possible adjustment of its dosage.</p></td>
</tr>

<tr>
<td valign="top"><p><b>POSACONAZOLE</b></p>

<p><b>RxNorm: 282446 </b></p>

<p><b>ATC: J02AC04</b></p></td>
<td valign="top"><p><b>H2 RECEPTOR ANTAGONISTS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>A02BA-001</b></p></td>
<td valign="top"><p>Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the H2 receptor antagonist</p></td>
<td valign="top"><p><b>Not recommended</b></p>

<p><b>--</b>only with the oral suspension form of posaconazole</p></td>
</tr>

<tr>
<td valign="top"><p><b>POSACONAZOLE</b></p>

<p><b>RxNorm: 282446 </b></p>

<p><b>ATC: J02AC04</b></p></td>
<td valign="top"><p><b>PROTON PUMP INHIBITORS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>A02BC-001</b></p></td>
<td valign="top"><p>Decrease of the absorption of the azole antifungal, due to increase of the gastric pH by the inhibitor</p></td>
<td valign="top"><p><b>Not recommended</b></p>

<p><b>--</b>only for the oral suspension form of posaconazole</p></td>
</tr>

<tr>
<td valign="top"><p><b>POSACONAZOLE</b></p>

<p><b>RxNorm: 282446 </b></p>

<p><b>ATC: J02AC04</b></p></td>
<td valign="top"><p><b>ATORVASTATIN</b></p>

<p><b>RxNorm: 83367 </b></p>

<p><b>ATC: C10AA05</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>POSACONAZOLE</b></p>

<p><b>RxNorm: 282446 </b></p>

<p><b>ATC: J02AC04</b></p></td>
<td valign="top"><p><b>DEXAMETHASONE</b></p>

<p><b>RxNorm: 3264 </b></p>

<p><b>ATC:</b></p>

<p><b>A01AC02 C05AA09 D07AB19 D07XB05 D10AA03 H02AB02 R01AD03 S01BA01 S01CB01 S02BA06 S03BA01</b></p></td>
<td valign="top"><p>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing’s syndrome</p></td>
<td valign="top"><p><b>Take into account</b></p>

</td>
</tr>

<tr>
<td valign="top"><p><b>POSACONAZOLE</b></p>

<p><b>RxNorm: 282446 </b></p>

<p><b>ATC: J02AC04</b></p></td>
<td valign="top"><p><b>DIGOXIN </b></p>

<p><b>RxNorm: 3407</b></p>

<p><b>ATC: C01AA05</b></p></td>
<td valign="top"><p>Increase of the digoxinemia with nausea, vomiting, arrhythmias.</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Clinical monitoring, and, if there is reason for them, EKG and monitoring of the digoxinemia, with adjustment of the dosage of the digoxin during the treatment with the posaconazole and after it is stopped<b>.</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>POSACONAZOLE</b></p>

<p><b>RxNorm: 282446 </b></p>

<p><b>ATC: J02AC04</b></p></td>
<td valign="top"><p><b>IMMUNOSUPPRESSANTS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>L04A</b></p></td>
<td valign="top"><p>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</p></td>
<td valign="top"><p><b>Not recommended</b></p>

<p>If these medications are administered together, strict testing of renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage<b>.</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>POSACONAZOLE</b></p>

<p><b>RxNorm: 282446 </b></p>

<p><b>ATC: J02AC04</b></p></td>
<td valign="top"><p><b>RIFABUTIN</b></p>

<p><b>RxNorm: 55672</b></p>

<p><b>ATC: J04AB04</b></p></td>
<td valign="top"><p>Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite</p></td>
<td valign="top"><p><b>Not recommended</b></p>

<p>Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together<b>. </b></p></td>
</tr>

<tr>
<td valign="top"><p><b>POSACONAZOLE</b></p>

<p><b>RxNorm: 282446 </b></p>

<p><b>ATC: J02AC04</b></p></td>
<td valign="top"><p><b>RIFAMPICIN</b></p>

<p><b>RxNorm: 9384 </b></p>

<p><b>ATC: J04AB02</b></p></td>
<td valign="top"><p>Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)</p></td>
<td valign="top"><p><b>Not recommended</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>POSACONAZOLE</b></p>

<p><b>RxNorm: 282446 </b></p>

<p><b>ATC: J02AC04</b></p></td>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)</p></td>
<td valign="top"><p><b>CONTRAINDICATION </b></p></td>
</tr>

<tr>
<td valign="top"><p><b>POSACONAZOLE</b></p>

<p><b>RxNorm: 282446 </b></p>

<p><b>ATC: J02AC04</b></p></td>
<td valign="top"><p><b>VINCA ALKALOIDS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>L01CA</b></p></td>
<td valign="top"><p>Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the posaconazole</p></td>
<td valign="top"><p><b>Not recommended</b></p></td>
</tr>

</tbody>
</table>

